Top Health Tech Companies in Dublin (91)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.
Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.
Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.
Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.
Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.
Medserv are the leading provider of medical billing and practice management services to consultants, consultant groups and hospitals throughout Ireland and the UK. Our innovative Smartphone App allows consultants to quickly and securely send us patient information, whilst also keeping track of your claims and payments. Medserv strives to improve the management of your private practice through: - Reducing your practice administration -...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Abi Global Health delivers telemedicine solutions in 37 countries across 6 continents. Our unique artificial intelligence and machine learning technology enables our network of over 1,000 healthcare professionals to provide quick answers to users in 24 languages across a choice of interfaces
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. For 90 years, we’ve been making an impact at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, therapies and...
Baxter International Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Baxter is a leader in U.S. IV solutions and a top contender in connected-care hospital beds and surgical hemostats, underscoring durable share in core hospital categories. This positioning supports resilience despite category- and region-specific competition.
Product Line Growth: Ongoing updates to infusion technologies and continued launches in injectables and advanced surgery indicate a healthy product refresh cadence. FDA clearances and connected-care enhancements help sustain installed-base momentum.
Future-Ready Strategy: Portfolio reshaping (Kidney Care divestiture) and new leadership focused on execution and continuous improvement signal a sharpened hospital-centric strategy. Deleveraging and supply-chain initiatives aim to improve stability and long-term growth capacity.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
Fettle is a digital behavioral healthcare company. We provide clients easy access to a diverse range of qualified and insured mental health professionals. Fettle was founded with the ideal that mental health is a universal need and that everyone struggles sometimes. Using technology and data science coupled with a human touch; Fettle enables seamless virtual delivery of mental health support....
Optum Insight provides technology-enabled services, advanced analytics, and platforms focused on the healthcare system to help customers reduce costs, manage risk and quality, and grow revenue. It aims to simplify and connect clinical, administrative, and financial processes within healthcare.
We are the creators of Complete Anatomy, the world’s most advanced 3D anatomy platform. Our revolutionary cloud-based platform allows users to investigate the details of the human anatomy in incredible 3D, transforming medical learning and practice across the world, leading the way in the production of ground-breaking 3D medical technology. Used by over 1,000,000 students, patients and professionals, our software...
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for...
Becton Dickinson's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly described as a leader across core categories like syringes, prefillable drug-delivery systems, blood collection, and infusion therapy, supported by broad global reach and large installed bases. This entrenched position aids customer stickiness and supports durable demand.
Resilient & Sustainable Growth: A substantial portion of revenue comes from everyday consumables and recurring platforms, which provides steadier sales through cycles. Consistent year-over-year revenue increases and diversified end-market exposure underpin an enduring growth profile.
Future-Ready Strategy: Management is reshaping the portfolio into a pure-play MedTech company and investing in manufacturing capacity and innovation to sharpen focus on higher-value growth areas. Guidance reaffirmations and targeted segment investments indicate disciplined execution toward long-term expansion.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
FDB (First Databank) creates and delivers the world’s most powerful drug knowledge that ignites, inspires, and illuminates critical medication decisions. We collaborate with our partners to help improve patient safety, operational efficiency, and health outcomes. Our drug databases drive healthcare information systems that serve the majority of hospitals, physician practices, pharmacies, payers, and all other areas of healthcare and are...
Pioneering chat-based AI wellness solutions since 2017. If you’d like to hear updates from Woebot Health, sign up here: https://woebothealth.com/woebot-health-updates/
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
Karo Healthcare delivers smart choices for everyday healthcare. We own and commercialise branded, original over-the-counter products and prescription medicines across a range of everyday categories, including intimate health; skin health; digestive health, foot health; pain, cough and cold; wellness; and specialty products. Our products are available in more than 90 countries and sold through pharmacies, retailers and via healthcare providers....
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
Integra LifeSciences, a world leader in medical technology with headquarters in Princeton, New Jersey, was founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has expanded its base regenerative technology product portfolio to include surgical instruments, neurosurgical products and advanced wound care products, through global acquisitions and development...
The Health Service Executive (HSE) is Ireland’s public health and social care service, providing quality care and support to people at all stages of life. Its responsibilities include vaccination and screening, hospital care, community and primary care, mental-health services, support for older adults and people with disabilities, medical-card schemes, and management of hospitals, healthcare professionals, community services, and the National...
